Daiichi Sankyo leads highly concentrated Enhertu market

The Enhertu market is dominated by Daiichi Sankyo and AstraZeneca, with the two companies accounting for all reported revenue in 2024, according to The Business Research Company. The report points to clinical-trial expansion, label growth and HER2-targeted strategy as the main forces shaping competition through 2035.

Why it matters: - The Enhertu market is highly concentrated, with two companies controlling all reported revenue in 2024. - The market’s direction affects how quickly HER2-targeted therapies expand across additional cancer types. - Competitive moves around clinical data, regulatory expansion and precision medicine are central to future market share.

What happened: - The Business Research Company released its Enhertu Market Report 2026, covering market size, trends and global forecast through 2035. - Daiichi Sankyo Co. Ltd. led global Enhertu sales in 2024 with a 67% market share. - AstraZeneca Plc. held the remaining 33% share. - The top 2 players accounted for 100% of total market revenue in 2024. - The report says the market is dominated by global pharmaceutical companies and specialized oncology therapy developers.

The details: - Daiichi Sankyo’s oncology portfolio centers on targeted antibody-drug conjugate therapies for precision oncology. - The report links market strength to clinical development, therapeutic innovation and treatment advancement in HER2-positive and HER2-low cancer segments. - Major raw material suppliers include FUJIFILM Diosynth Biotechnologies, AGC Biologics, Lonza Group, Samsung Biologics, Catalent Inc., WuXi Biologics, Thermo Fisher Scientific Inc., Cytiva and Merck KGaA. - Other listed suppliers include Ajinomoto Bio-Pharma Services, Evonik Industries AG, CordenPharma International, Piramal Pharma Solutions, Recipharm AB, Asymchem Laboratories, Sai Life Sciences Ltd., Boehringer Ingelheim BioXcellence, AbbVie Contract Manufacturing, Alcami Corporation and Danaher Corporation. - Major wholesalers and distributors include Cencora Inc., Cardinal Health Inc., Morris & Dickson Co. LLC, Anda Inc., Oncology Supply, Besse Medical, FFF Enterprises Inc., Smith Drug Company, CuraScript SD and ASD Healthcare. - Other distributors named in the report include Medline Industries LP, Pharmaceutical Associates Inc., Value Drug Company, Henry Schein Inc., McKesson Specialty Health, Cardinal Health Specialty Pharmaceutical Distribution, BioCareSD, McKesson Plasma and Biologics LLC and ASD Specialty Healthcare. - Major end users include MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Stanford Health Care, Mass General Cancer Center, City of Hope and Cedars-Sinai Cancer. - Other end users listed include Northwestern Medicine Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, The Royal Marsden NHS Foundation Trust, Gustave Roussy, Charité – Universitätsmedizin Berlin, Princess Margaret Cancer Centre, National Cancer Center Hospital Japan, Apollo Hospitals, Fortis Healthcare and Tata Memorial Hospital. - The report says the market remains highly concentrated because of complex biologic manufacturing, targeted oncology research spending, intellectual property protection and the need for clinical validation.

Between the lines: - Clinical trial expansion is becoming the main competitive lever because it can broaden indications and strengthen evidence for new patient groups. - In April 2024, Daiichi Sankyo and AstraZeneca reported DESTINY-Breast06 Phase 3 results for ENHERTU in hormone receptor-positive, HER2-low metastatic breast cancer after endocrine therapy. - The report says the trial showed statistically significant progression-free survival improvement. - The report frames that data as support for broader HER2-targeted treatment strategies and precision medicine adoption. - The concentration of revenue in two players suggests that future gains may depend more on label expansion and evidence generation than on simple market entry.

What's next: - Companies are pursuing expansion of HER2-targeted therapies across multiple cancer indications. - Clinical trial advancements are expected to keep shaping oncology treatment applications. - Strategic collaborations are likely to remain important for antibody-drug conjugate development. - Precision medicine integration and regulatory label expansions are expected to support broader patient access and adoption. - The report says pipeline expansion, strategic alliances and indication development should strengthen the position of leading companies.

The bottom line: - Enhertu remains a tightly held oncology market where clinical data and new indications are the main paths to growth. - Request a free sample of the report - Access the detailed market report